Predictive marker for antiviral therapy using HCV genome analysis

探讨丙型肝炎病毒基因突变与聚乙二醇化干扰素(PEG化干扰素)联合利巴韦林(RBV)治疗慢性丙型肝炎疗效的关系。干扰素敏感性决定区(ISDR)或干扰素/利凡韦林耐药决定区(IRRDR)、Core70和Core91的氨基酸残基突变与疗效相关。此外，位于IL28B基因附近的单核苷酸多态(SNPs)与1型患者对聚乙二醇化干扰素/RBV治疗的反应密切相关。近年来，丙型肝炎病毒的蛋白水解酶抑制剂替拉普韦(TVR)相继问世，这些突变对预测聚乙二醇-干扰素+RBV+TVR三联疗法的疗效具有重要意义。

We clarified the relation between HCV gene mutations and therapeutic effect of pegylated interferon(PEG-IFN) plus ribavirin(RBV) combination therapy for chronic hepatitis C. Number of mutations in the interferon sensitivity determining region(ISDR) or interferon/rivavirin resistance determining region(IRRDR) in HCV-5A, and amino acid substation of Core70 and Core 91 were correlated to therapeutic effect. Moreover, single nucleotide polymorphisms(SNPs) located near the IL28B gene were strongly associated with a response to PEG-IFN/RBV therapy in genotype 1 patients. In recent years, HCV protease inhibitor, Telaprevir(TVR) became available for HCV, these mutations were also important to predict therapeutic effect in triple therapy of PEG-IFN+RBV+TVR.